Phibro Animal Health Corporation $PAHC Shares Sold by Ranger Investment Management L.P.

Ranger Investment Management L.P. lessened its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 16.2% in the 3rd quarter, Holdings Channel reports. The fund owned 299,910 shares of the company’s stock after selling 58,060 shares during the quarter. Ranger Investment Management L.P.’s holdings in Phibro Animal Health were worth $12,134,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares in the last quarter. Millennium Management LLC boosted its stake in Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares during the last quarter. Jane Street Group LLC grew its holdings in Phibro Animal Health by 65.3% in the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after buying an additional 13,404 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Phibro Animal Health by 7.6% in the 2nd quarter. State of Alaska Department of Revenue now owns 12,129 shares of the company’s stock worth $309,000 after acquiring an additional 859 shares during the last quarter. Finally, Yousif Capital Management LLC purchased a new position in shares of Phibro Animal Health during the 2nd quarter worth $200,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PAHC has been the subject of a number of analyst reports. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and an average price target of $31.40.

Insider Activity

In related news, CEO Jack Bendheim sold 3,520 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00. Following the transaction, the chief executive officer owned 48,800 shares of the company’s stock, valued at approximately $2,008,120. This represents a 6.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 170,720 shares of company stock valued at $7,340,425. 50.13% of the stock is currently owned by insiders.

Phibro Animal Health Trading Up 3.6%

Shares of PAHC stock opened at $51.78 on Friday. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $50.05. The firm has a market cap of $2.10 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 1.16 and a beta of 0.80. The company has a 50-day moving average of $39.88 and a two-hundred day moving average of $38.14. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.69 by $0.18. The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 39.76%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is presently 28.92%.

Phibro Animal Health News Roundup

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Q2 results beat expectations: EPS $0.87 vs. $0.69 consensus and net sales $373.9M (up 21% year-over-year), driven by broad sales growth and margin improvement — a core reason the stock rallied. Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
• Positive Sentiment: Management raised FY2026 EPS guidance to $2.93–$3.10 (consensus ~2.75) while keeping revenue guidance roughly in line with expectations — the stronger EPS outlook amplified the upside move. Phibro Animal Health (PAHC) Is Up 25.3% After Issuing 2026 Sales And EPS Guidance – What’s Changed
• Neutral Sentiment: Investor materials are available (earnings slide deck and call transcript) for diligence — useful for checking segment-level trends and management commentary on organic growth and cost leverage. Phibro Animal Health Corporation 2026 Q2 – Results – Earnings Call Presentation Phibro Animal Health Corporation (PAHC) Q2 2026 Earnings Call Transcript
• Negative Sentiment: Insider selling: CEO Jack Bendheim disclosed sales on Feb 3–4 totaling 13,180 shares (two filings), materially reducing his holding; some investors view insider sales as a cautionary signal even if proceeds may fund taxes/estate planning. SEC Filing Disclosing Insider Sales
• Negative Sentiment: Independent research note flagged a more cautious view (Zacks expressed pessimism on the quarter) — divergent analyst sentiment could lead to volatility as investors parse sustainability of margin and guidance assumptions. Zacks Research Has Pessimistic Outlook of PAHC Q2 Earnings

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.